1.
Product
Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for
Study
1.2.3.
Key Market
Segmentations
2.
Research
Methodology
2.1.
Objective of
the Study
2.2.
Baseline
Methodology
2.3.
Key Industry
Partners
2.4.
Major
Association and Secondary Sources
2.5.
Forecasting
Methodology
2.6.
Data
Triangulation & Validation
2.7.
Assumptions
and Limitations
3.
Executive
Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4.
Voice of Customer
5. Global Active Pharmaceutical Ingredients CDMO Market Outlook
5.1.
Market Size & Forecast
5.1.1.
By Value
5.2.
Market Share & Forecast
5.2.1.
By Molecule Type (Small Molecule, Large Molecule)
5.2.2.
By Synthesis
(Biotech, Synthetic)
5.2.3.
By Drug
Type (Innovative, Generics)
5.2.4.
By Workflow
(Clinical, Commercial)
5.2.5.
By Application
(Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
5.2.6.
By Region (North America, Europe, Asia Pacific, South
America, Middle East & Africa)
5.2.7.
By Company (2023)
5.3.
Market Map
5.3.1 By Molecule
Type
5.3.2
By Synthesis
5.3.3
By Drug Type
5.3.4
By Workflow
5.3.5
By Application
5.3.6 By Region
6. North America Active
Pharmaceutical Ingredients CDMO Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1.
By Molecule Type (Small Molecule, Large Molecule)
6.2.2.
By Synthesis
(Biotech, Synthetic)
6.2.3.
By Drug
Type (Innovative, Generics)
6.2.4.
By Workflow
(Clinical, Commercial)
6.2.5.
By Application
(Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
6.2.6.
By Country
6.3.
North America: Country Analysis
6.3.1.
United States Active Pharmaceutical Ingredients CDMO
Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Molecule Type
6.3.1.2.2.
By Synthesis
6.3.1.2.3.
By Drug Type
6.3.1.2.4.
By Workflow
6.3.1.2.5.
By Application
6.3.2.
Canada Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Molecule Type
6.3.2.2.2.
By Synthesis
6.3.2.2.3.
By Drug Type
6.3.2.2.4.
By Workflow
6.3.2.2.5.
By Application
6.3.3.
Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Molecule Type
6.3.3.2.2.
By Synthesis
6.3.3.2.3.
By Drug Type
6.3.3.2.4.
By Workflow
6.3.3.2.5.
By Application
7. Europe Active
Pharmaceutical Ingredients CDMO Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1.
By Molecule Type (Small Molecule, Large Molecule)
7.2.2.
By Synthesis
(Biotech, Synthetic)
7.2.3.
By Drug
Type (Innovative, Generics)
7.2.4.
By Workflow
(Clinical, Commercial)
7.2.5.
By Application
(Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
7.2.6.
By Country
7.3.
Europe: Country Analysis
7.3.1.
France Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Molecule Type
7.3.1.2.2.
By Synthesis
7.3.1.2.3.
By Drug Type
7.3.1.2.4.
By Workflow
7.3.1.2.5.
By Application
7.3.2.
Germany Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Molecule Type
7.3.2.2.2.
By Synthesis
7.3.2.2.3.
By Drug Type
7.3.2.2.4.
By Workflow
7.3.2.2.5.
By Application
7.3.3.
United Kingdom Active Pharmaceutical Ingredients CDMO
Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Molecule Type
7.3.3.2.2.
By Synthesis
7.3.3.2.3.
By Drug Type
7.3.3.2.4.
By Workflow
7.3.3.2.5.
By Application
7.3.4.
Italy Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Molecule Type
7.3.4.2.2.
By Synthesis
7.3.4.2.3.
By Drug Type
7.3.4.2.4.
By Workflow
7.3.4.2.5.
By Application
7.3.5.
Spain Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Molecule Type
7.3.5.2.2.
By Synthesis
7.3.5.2.3.
By Drug Type
7.3.5.2.4.
By Workflow
7.3.5.2.5.
By Application
8. Asia Pacific Active
Pharmaceutical Ingredients CDMO Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Molecule Type (Small Molecule, Large Molecule)
8.2.2.
By Synthesis
(Biotech, Synthetic)
8.2.3.
By Drug
Type (Innovative, Generics)
8.2.4.
By Workflow
(Clinical, Commercial)
8.2.5.
By Application
(Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
8.2.6.
By Country
8.3.
Asia Pacific: Country Analysis
8.3.1.
China Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Molecule Type
8.3.1.2.2.
By Synthesis
8.3.1.2.3.
By Drug Type
8.3.1.2.4.
By Workflow
8.3.1.2.5.
By Application
8.3.2.
India Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Molecule Type
8.3.2.2.2.
By Synthesis
8.3.2.2.3.
By Drug Type
8.3.2.2.4.
By Workflow
8.3.2.2.5.
By Application
8.3.3.
Japan Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Molecule Type
8.3.3.2.2.
By Synthesis
8.3.3.2.3.
By Drug Type
8.3.3.2.4.
By Workflow
8.3.3.2.5.
By Application
8.3.4.
South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Molecule Type
8.3.4.2.2.
By Synthesis
8.3.4.2.3.
By Drug Type
8.3.4.2.4.
By Workflow
8.3.4.2.5.
By Application
8.3.5.
Australia Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Molecule Type
8.3.5.2.2.
By Synthesis
8.3.5.2.3.
By Drug Type
8.3.5.2.4.
By Workflow
8.3.5.2.5.
By Application
9. South America Active
Pharmaceutical Ingredients CDMO Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1.
By Molecule Type (Small Molecule, Large Molecule)
9.2.2.
By Synthesis
(Biotech, Synthetic)
9.2.3.
By Drug
Type (Innovative, Generics)
9.2.4.
By Workflow
(Clinical, Commercial)
9.2.5.
By Application
(Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
9.2.6.
By Country
9.3.
South America: Country Analysis
9.3.1.
Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Molecule Type
9.3.1.2.2.
By Synthesis
9.3.1.2.3.
By Drug Type
9.3.1.2.4.
By Workflow
9.3.1.2.5.
By Application
9.3.2.
Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Molecule Type
9.3.2.2.2.
By Synthesis
9.3.2.2.3.
By Drug Type
9.3.2.2.4.
By Workflow
9.3.2.2.5.
By Application
9.3.3.
Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Molecule Type
9.3.3.2.2.
By Synthesis
9.3.3.2.3.
By Drug Type
9.3.3.2.4.
By Workflow
9.3.3.2.5.
By Application
10. Middle East and
Africa Active Pharmaceutical Ingredients CDMO Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1.
By Molecule Type (Small Molecule, Large Molecule)
10.2.2.
By Synthesis
(Biotech, Synthetic)
10.2.3.
By Drug
Type (Innovative, Generics)
10.2.4.
By Workflow
(Clinical, Commercial)
10.2.5. By Application (Cardiology, Oncology,
Ophthalmology, Neurology, Orthopedic, Other)
10.2.6.
By Country
10.3.
MEA: Country Analysis
10.3.1.
South Africa Active Pharmaceutical Ingredients CDMO
Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Molecule Type
10.3.1.2.2.
By Synthesis
10.3.1.2.3.
By Drug Type
10.3.1.2.4.
By Workflow
10.3.1.2.5.
By Application
10.3.2.
Saudi Arabia Active Pharmaceutical Ingredients CDMO
Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Molecule Type
10.3.2.2.2.
By Synthesis
10.3.2.2.3.
By Drug Type
10.3.2.2.4.
By Workflow
10.3.2.2.5.
By Application
10.3.3. UAE Active
Pharmaceutical Ingredients CDMO Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Molecule Type
10.3.3.2.2.
By Synthesis
10.3.3.2.3.
By Drug Type
10.3.3.2.4.
By Workflow
10.3.3.2.5.
By Application
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Development
12.2.
Mergers &
Acquisitions
12.3.
Product Launches
13. Global
Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis
14. Porter’s
Five Forces Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Products
15.
Competitive Landscape
15.1.
Cambrex Corporation
15.1.1.
Business Overview
15.1.2.
Products & Services
15.1.3.
Recent Developments
15.1.4.
Financials (As Reported)
15.1.5.
Key Personnel
15.1.6.
SWOT Analysis
15.2.
Thermo Fisher Scientific, Inc.
15.3.
Recipharm AB
15.4.
Corden Pharma International GmbH
15.5.
Samsung Biologics Co., Ltd.
15.6.
Lonza Group Ltd.
15.7.
Siegfried Holding AG
15.8.
Piramal Pharma Limited
15.9.
AbbVie Inc.
15.10. Catalent, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer